The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age40-70
SponsorPoznan University of Medical Sciences
About this trial
Numerous studies, but not all, have suggested a positive effect of allopurinol on the cardiovascular system. The ALL-VASCOR study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in patients at high and very high cardiovascular risk, excluding ischemic heart disease. This is particularly important due to the high cost of cardiovascular disease treatment and its status as one of the leading causes of death.
Eligibility criteria
Qualifiers
Age: between 40-70 years old.
Giving informed consent to participate in the study.
Serum UA levels above 5 mg/dl within the last six months before the screening visit.
calculated 10-year cardiovascular mortality risk based on SCORE2 >2.5% for patients under 50 years old or ≥5% for patients 50 years old or older
Disqualifiers
Taking allopurinol, febuxostat or other hypouricemic drugs.
Contraindications to taking allopurinol.
Pregnant women, breastfeeding or planning pregnancy during the duration of the study.
Hormonal therapy containing oestrogens.
Trial design
Treatments tested in this trial
- Allopurinol 200 mg
- Optional intervention
Treatment groups
1,116 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov